Biotech entity
Eli Lilly is the most frequent co-covered peer, appearing in 2 of the 3 tracked stories. They are better corroborated than the beat average, carrying 9 original sources each against 3.6 for the same window. fda-approval accounts for 2 of the 3 tracked stories, while 1 other category carries the remainder.
Last mentioned: 1h ago
Entity pulse
Coverage balance Balanced directional read. Positive and negative coverage are within 0 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Eli Lilly is the most frequent co-covered peer, appearing in 2 of the 3 tracked stories. They are better corroborated than the beat average, carrying 9 original sources each against 3.6 for the same window. fda-approval accounts for 2 of the 3 tracked stories, while 1 other category carries the remainder. That works out to roughly 0.1 stories per week across a 165-day span. At 6.3, the average consequence score sits above the same-window beat average of 6.1. This profile follows 3 Biotech stories mentioning Zepbound across the period from March 13, 2026 to August 24, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 502 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Zepbound. Shared-story counts are live from our verified record — not editorial picks.
Publication of Articles
Two sources publish analyses on reasons to buy Eli Lilly stock, highlighting recent performance and future prospects
Duquesne Family Office initiates RYTM position
In Q2 2026, Stanley Druckenmiller's investment firm discloses a new stake in Rhythm Pharmaceuticals.
FDA expands Imcivree approval to Bardet-Biedl syndrome
The indication is expanded to cover obesity associated with Bardet-Biedl syndrome.
FDA approves Imcivree for POMC deficiency
Imcivree receives U.S. approval for chronic weight management in patients with proopiomelanocortin deficiency.
Biotech investors are tracking Rhythm Pharmaceuticals after Duquesne Family Office disclosed a Q2 2026 stake. Imcivree's 2020 and 2022 FDA approvals for POMC deficiency and Bardet-Biedl syndrome give RYTM an orphan monopoly in a niche GLP-1 leaders can't enter.
Source: finance.yahoo.com · fool.com
Eli Lilly's innovative drug pipeline, including treatments for obesity and diabetes, positions it as a leader in biotech, with stock gains of 25% year-to-date signaling strong potential. For biotech professionals, this highlights the impact of clinical successes on market value and future R&D investments. Regulatory contexts like FDA approvals could further accelerate Eli Lilly's dominance in gene therapy and personalized medicine.
Source: fool.com · finance.yahoo.com
Eli Lilly has issued a formal warning regarding "potentially dangerous" impurities discovered in compounded versions of its tirzepatide-based medications, Mounjaro and Zepbound. The company’s internal testing revealed significant safety risks in off-brand formulations, intensifying the ongoing conflict between big pharma and compounding pharmacies.
Zepbound is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
